Erik Manting
Amministratore Delegato presso MENDUS AB
Patrimonio netto: 69 534 $ in data 31/05/2024
Profilo
Dr. Erik Manting is an Independent Director at TransCode Therapeutics, Inc. and a Chief Executive & Business Officer at Mendus AB.
He is on the Board of Directors at TransCode Therapeutics, Inc. and Synerkine Pharma BV.
Dr. Manting was previously employed as a Founder by Bioentrepreneur BV, a Chief Executive Officer by DCPrime BV, an Executive Director-Life Sciences & Healthcare by Kempen & Co. NV, and an Analyst by Rabo Securities NV.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
MENDUS AB
0.14% | 31/12/2022 | 1 442 312 ( 0.14% ) | 69 534 $ | 31/05/2024 |
| 14/06/2024 | 0 ( -.--% ) | - $ | 31/05/2024 |
Posizioni attive di Erik Manting
| Società | Posizione | Inizio |
|---|---|---|
| MENDUS AB | Amministratore Delegato | 16/03/2021 |
| TRANSCODE THERAPEUTICS, INC. | Direttore/Membro del Consiglio | 20/12/2020 |
Synerkine Pharma BV
 Synerkine Pharma BV Miscellaneous Commercial ServicesCommercial Services Synerkine Pharma BV focuses on developing novel fusion proteins for the treatment of inflammatory, neuropathic and osteoarthritic pain. The company was founded by Hans Preusting in 2018 and is headquartered in Utrecht, Netherlands. | Direttore/Membro del Consiglio | 01/03/2019 |
Precedenti posizioni note di Erik Manting
| Società | Posizione | Fine |
|---|---|---|
DCPrime BV
 DCPrime BV Pharmaceuticals: MajorHealth Technology DCPrime BV engages in the provision of therapeutic vaccines for the treatment of cancer. It develops whole-cell-based vaccine addressing blood cancers with a high risk of relapse. The company was founded by Ada M. Kruisbeek and Rik J. Scheper in March 2005 and is headquartered in Leiden, the Netherlands. | Amministratore Delegato | 01/12/2020 |
Kempen & Co. NV
 Kempen & Co. NV Financial ConglomeratesFinance Kempen & Co. NV provides financial services to professional investors. The company's clients include institutional investors, companies, financial institutions, public & semi-public institutions, foundations and high-net-worth private clients. The company was founded in July 1903 by A. J. Kempen and M. D. de Lange and is headquartered in Amsterdam, The Netherlands. | Corporate Officer/Principal | 01/09/2017 |
| Rabo Securities NV | Analyst-Equity | 14/09/2005 |
| Bioentrepreneur BV | Fondatore | - |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| MENDUS AB | Health Technology |
| Aziende private | 6 |
|---|---|
Kempen & Co. NV
Kempen & Co. NV Financial ConglomeratesFinance Kempen & Co. NV provides financial services to professional investors. The company's clients include institutional investors, companies, financial institutions, public & semi-public institutions, foundations and high-net-worth private clients. The company was founded in July 1903 by A. J. Kempen and M. D. de Lange and is headquartered in Amsterdam, The Netherlands. | Finance |
| Rabo Securities NV | Finance |
DCPrime BV
DCPrime BV Pharmaceuticals: MajorHealth Technology DCPrime BV engages in the provision of therapeutic vaccines for the treatment of cancer. It develops whole-cell-based vaccine addressing blood cancers with a high risk of relapse. The company was founded by Ada M. Kruisbeek and Rik J. Scheper in March 2005 and is headquartered in Leiden, the Netherlands. | Health Technology |
Synerkine Pharma BV
Synerkine Pharma BV Miscellaneous Commercial ServicesCommercial Services Synerkine Pharma BV focuses on developing novel fusion proteins for the treatment of inflammatory, neuropathic and osteoarthritic pain. The company was founded by Hans Preusting in 2018 and is headquartered in Utrecht, Netherlands. | Commercial Services |
| TransCode Therapeutics, Inc. | |
| Bioentrepreneur BV |
- Borsa valori
- Insiders
- Erik Manting
